Drug Database
AN

Anti-D immunoglobulin (Vinobulin)

✓ Approved

Bharat Serums and Vaccines Limited · Polyclonal Antibodies · Polyclonal Antibodies

What is Anti-D immunoglobulin?

Anti-D immunoglobulin is a polyclonal antibodies developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesVinobulin
CompanyBharat Serums and Vaccines Limited
Drug ClassPolyclonal Antibodies, Cell-based Therapies, Antibody
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Bharat Serums and Vaccines Limited

Therapeutic Indications

Anti-D immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

Related Research Articles

PubMedJournal of clinical laboratory analysis2026-10-22

The Impact of Immunoglobulins on Cardiovascular Diseases and Lipid Profiles in Elderly and Middle-Aged Chinese Individuals: A 15-Year Retrospective Study.

Li Ya Y, Jiao Li L, Gao Yuan Y, Ni Xue-Feng XF

Humoral immunity defends via immunoglobulins. This study aimed to evaluate the association between immunoglobulins and CVDs and lipid profiles in a cohort of individuals aged 45 years and older. Data from 982 subjects were analyzed. The cohort had a median age of 61 years (IQR 56-72), was predominantly male (84.8%), and had a high prevalence of CVDs at baseline, including hypertension (30.3%), dyslipidemia (20.7%), arrhythmia (22.3%), coronary heart disease (12.1%), and atrial fibrillation (4.5%). Logistic regression analysis was used to examine the association between baseline and time-varying serum levels of IgG, IgA, and IgM and the presence of five CVDs: coronary heart disease, atrial fibrillation, arrhythmia, hypertension, and dyslipidemia. We additionally explored the relationship between these immunoglobulin levels and lipid profiles. No significant differences in immunoglobulin levels were found between CVD and non-CVD groups at baseline, and baseline immunoglobulin levels were not associated with any CVD. However, longitudinal changes in IgG and IgA levels were positively associated with changes in free fatty acids (FFAs). Intriguingly, longitudinal increases in IgM levels were positively associated with total cholesterol, LDL-C, non-HDL-C, and HDL-C. This study provides longitudinal evidence that increases in IgG and IgA levels are associated with elevated FFA levels, while increases in IgM are associated with an adverse lipid profile characterized by higher total cholesterol, LDL-C, and non-HDL-C, and lower HDL-C. These findings suggest a link between humoral immunity and lipid metabolism that warrants further investigation, with potential implications for cardiovascular risk assessment.

PMID 42902915
Read full article →
PubMedFrontiers in immunology2026-10-22

Case Report: Acute liver failure in systemic lupus erythematosus with autoimmune hepatitis-primary biliary cholangitis overlap: a belimumab-containing regimen and longitudinal follow-up.

Zhang Lina L, Zhang Tong T, Zhang Jing J, Wang Xiuhong X et al.

Severe autoimmune liver injury as the first manifestation of systemic lupus erythematosus (SLE) is rare, and concomitant autoimmune hepatitis-primary biliary cholangitis (AIH-PBC) overlap is uncommon. B-cell-activating factor (BAFF) provides a biological rationale for adjunctive therapy, although clinical evidence remains limited. A 72-year-old woman presented with 4 weeks of fatigue and anorexia and developed coagulopathy (international normalized ratio [INR] 1.8), ascites, and hepatic encephalopathy. Autoimmune testing showed antinuclear antibody 1:1280, high-titer anti-double-stranded DNA antibodies with hypocomplementemia, immunoglobulin G (IgG) 30.0 g/L, and antimitochondrial antibody positivity. Hepatitis B surface antigen, hepatitis C antibody, hepatitis E antibody, and Epstein-Barr virus and cytomegalovirus DNA tests were negative. Liver biopsy 42 days after corticosteroid initiation demonstrated interface hepatitis, destructive small-bile-duct injury, plasma cell-rich inflammation, and Batts-Ludwig stage 2 fibrosis without cirrhosis, supporting a clinicopathologic diagnosis of AIH-PBC overlap. Previously unrecognized chronic autoimmune liver disease could not be excluded. Prednisolone was started at 50 mg/day, followed 10 days later by intravenous belimumab, with concomitant ursodeoxycholic acid. Tacrolimus was added during maintenance. By 10 October 2025, liver biochemistry had improved, IgG was 9.42 g/L, and prednisolone had been reduced to 2.5 mg/day. Liver stiffness decreased from 21.5 to 9.7 kPa. Sustained biochemical improvement occurred during a belimumab-containing multidrug regimen. This observation does not establish the independent efficacy of belimumab or histological regression of fibrosis.

PMID 42903101
Read full article →
PubMedFly2026-10-22

From bench to farm: leveraging Drosophila as a model insect for agricultural pest management.

Cai Yao D YD, Chiu Joanna C JC

The vinegar fly, Drosophila melanogaster, has contributed tremendously to advancing our understanding of the fundamentals of biology, from the chromosomal theory of inheritance to the survival of multi-cellular organisms in spaceflight. The use of this insect as a model organism has provided insights into all branches of life sciences, including agricultural and environmental sciences. In the context of integrated pest management (IPM), which often relies on species-specific natural history and phenology of pest insects and biological control, D. melanogaster flies have continued to be a powerhouse. In this review, we seek to summarize the use of the D. melanogaster model in studying insect biology relevant to IPM, with a focus on investigating the mechanisms underlying insecticide resistance. We sample case studies that adopt forward genetic approaches to reveal molecular underpinnings of IPM-relevant phenotypes and reverse genetic approaches that elucidate genotype-phenotype relationships. In particular, we highlight the contribution of D. melanogaster in understanding the biology and in developing IPM for the spotted-wing drosophila, also known as D. suzukii, a pest Drosophila species that devastates fruit production worldwide. Finally, we summarize recently developed research tools and resources in D. melanogaster that have potential utility for agricultural pest management.

PMID 42902760
Read full article →
PubMedJournal of microbiology and biotechnology2026-10-22

Live and Heat-Killed Lactiplantibacillus plantarum HY7715 Attenuate D-Galactose-Induced Aging-Related Brain Changes and Blood-Brain Barrier Disruption with Gut Microbiota Modulation in Mice.

Baik Jimin J, Gwon Hyeonjun H, Kim Joo-Yun JY, Shim Jae-Jung JJ et al.

Aging is associated with changes in systemic homeostasis, intestinal barrier integrity, and brain function. This study investigated the effects of Lactiplantibacillus plantarum HY7715 on aging-related alterations in a D-galactose-induced accelerated aging mouse model. Male C57BL/6J mice were administered D-galactose for 8 weeks and orally treated with live or heat-killed HY7715. D-galactose increased circulating advanced glycation end products (AGEs), blood-brain barrier (BBB) permeability, hippocampal inflammation, and aging-related molecular changes, while impairing cortical and colonic tight junction-associated markers. Both live and heat-killed HY7715 reduced serum AGE levels, Evans blue leakage, and hippocampal inflammatory responses, while restoring CLDN5 immunoreactivity, tight junction-associated gene expression, and antioxidant-related gene expression. HY7715 also attenuated senescence- and apoptosis-related changes in the hippocampus and colonic tight junction- and inflammation-related gene expression changes. Gut microbiota analysis showed taxon-specific changes following HY7715 treatment, including significant increases in Bifidobacterium in both HY7715-treated groups, whereas live HY7715 was associated with significant changes in microbial community structure. Several microbial taxa were correlated with serum AGEs, BBB permeability, and neuroinflammation-related parameters. Together, these results show that both live and heat-killed HY7715 attenuated multiple aging-related changes in the D-galactose-induced accelerated aging model, accompanied by changes in gut microbiota composition.

PMID 42902892
Read full article →
PubMedFrontiers in immunology2026-10-22

Vitiligo onset following anti-inflammatory biological therapy: a scoping review.

Romagnuolo Maurizio M, Moltrasio Chiara C, Rossi Luisa Carlotta LC, Tavoletti Gianluca G et al.

Vitiligo is a chronic autoimmune depigmentation skin disorder characterized by the acquired loss of melanocytes, with a complex multifactorial pathophysiology. Among the potential predisposing factors, some drugs, including monoclonal antibodies, have been associated to disease onset. The aim of the present review is to summarize and discuss current literature findings in de novo vitiligo following biological targeting inflammatory cytokines. Overall, 18 articles were considered eligible for the present review, and details of demographics, clinical characteristics, vitiligo type and localization, biological drug administered and treatment outcomes were reported.The mean age of the 39 patients was 43 years (±16.3), with a male predominance (62%). Tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, adalimumab, certolizumab pegol) were the most frequent suspected drugs (>50% of patients), followed by anti-IL-17A (ixekizumab, secukinumab) and anti-IL-12/23 (ustekinumab). Four cases were linked to anti-IL-4/13 (dupilumab). The median onset of vitiligo was 5 months post-initiation (range 1.5-24), with one-third of cases involving the face and neck, and two cases of segmental vitiligo. Biologic discontinuation or switching occurred in 26% of cases. Regarding outcomes, 41% experienced stabilization, 36% achieved varying degrees of repigmentation, and 8% progressed. While de novo vitiligo is reported as a potential adverse event of biological therapies, evidence for a direct causal relationship remains weak, with cases involving non-anti-TNFα agents appearing anecdotal. The co-occurrence of underlying autoimmune comorbidities in these patients points towards a coincidental rather than a causal relationship, highlighting the need for further research to fully elucidate this association.

PMID 42903092
Read full article →
PubMedAmyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis2026-10-22

Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study.

Obici Laura L, Damy Thibaud T, Galan Lucia L, Moody William W et al.

Transthyretin (ATTR) and immunoglobulin light-chain (AL) amyloidosis are progressive conditions that can have debilitating effects on people. Delayed diagnosis and variable access to high-quality care continue to affect quality of life and prognosis. Clear and ambitious quality standards could drive consistent care and improve outcomes. A modified nominal group technique was used to develop consensus-based quality standards for the diagnosis and management of ATTR and AL amyloidosis. Eighteen experts participated, including patient representatives and clinicians from high-income, publicly funded health systems in Europe and Canada. Each quality standard was paired with at least one measurable indicator to support implementation and monitoring. A total of 29 provisional statements were generated, with consensus achieved on eight quality standards. These span the full care pathway and emphasise the need for timely, person-centred and interdisciplinary care. Twenty accompanying indicators were developed. This is the first comprehensive set of consensus-based quality standards for ATTR and AL amyloidosis care. They provide a practical and aspirational framework to guide quality improvement across health systems. Adoption of these standards could improve early diagnosis, equitable access to treatment, and quality of life. Future research may explore their feasibility and adaptation for other health system settings.

PMID 42902796
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Anti-D immunoglobulin